Strychni Liquid Extract Veterinary Grade API is a standardized hydroalcoholic liquid extract of the dried ripe seeds of Strychnos nux-vomica L., supplied as an active pharmaceutical ingredient for the manufacture of veterinary tablets, injections, capsules, powders, granules, premix, and solutions. The extract is standardised to total alkaloid content expressed as strychnine; the principal alkaloids are strychnine and brucine, and the brucine fraction is reported batch-wise because it influences both pharmacological activity and analytical interference in finished-product testing. The material is not a simple solution of an isolated strychnine salt. It retains co-extracted botanical constituents that alter pH, filterability, precipitation behaviour, and assay response in aqueous and hydroalcoholic vehicles. A “model” designation is not customarily assigned under pharmacopoeial nomenclature; the batch number, product code, and certificate of analysis serve as the primary identifiers. The liquid presentation reduces airborne alkaloid dust during dispensing relative to powdered nux vomica extract, but a spill creates a high-contact-hazard contamination zone requiring validated deactivation and cleaning.

What specification thresholds limit the total alkaloid fraction, solvent content, and microbiological burden?

The release specification for the liquid extract is contractually fixed between the extract supplier and the veterinary dosage-form manufacturer. Legacy pharmacopoeial monographs for nux vomica liquid extract have described total alkaloid content of 1.0% w/v calculated as strychnine; a typical acceptance window of 0.95–1.05% w/v is used at batch release. The assay is performed by reversed-phase HPLC using a C18 stationary phase of 5 µm particle size and 250 × 4.6 mm column geometry, an acetonitrile–phosphate buffer mobile phase at pH 3.0, and UV detection at 254 nm. Validation follows ICH Q2(R1), with specificity demonstrated against brucine, linearity over 50–150% of nominal strychnine concentration, and accuracy and repeatability determined in the presence of the extract matrix. Ethanol content is measured by gas chromatography with flame ionisation detection under conditions aligned to USP <611>; the hydroalcoholic vehicle typically contains 60–70% v/v ethanol. Methanol and isopropanol are controlled as residual solvents under VICH GL18. Water content is determined by Karl Fischer titration per Ph. Eur. 2.5.12 and reported as a batch-release value, with the upper limit defined by process capability data rather than a universal figure. Microbiological release is commonly assigned according to Ph. Eur. 5.1.4 for oral liquids.

In addition to the tabulated parameters, the release specification includes appearance, visible particulate matter, and container-closure integrity for the supplier’s primary container. Forced degradation studies should include acid, base, oxidative, thermal, and photolytic stress on the liquid extract to demonstrate that the HPLC method separates strychnine and brucine from degradation products. Alkaline stress is particularly relevant because alkaloid precipitation and degradation can occur at pH above 8.0; the method must show adequate resolution for the principal degradation peak. System suitability criteria typically include a resolution factor between strychnine and brucine of not less than 1.5, tailing factor not more than 2.0, and relative standard deviation of replicate standard injections not more than 1.0%. Because the extract is toxic, the certificate of analysis should also report a batch-specific density value to convert volumetric metering into mass-based batch charging. Density is determined at 20 °C using a calibrated pycnometer or oscillating U-tube density meter; bulk homogenisation of received containers using a drum roller at 10–20 rpm for 4–8 h is common before sampling.

Within a multi-product veterinary manufacturing suite, the dominant process risk is not extract assay failure but cross-contamination of subsequent non-strychnine batches. Strychnine acts as a competitive antagonist at glycine receptors and has an extremely narrow toxicological threshold; therefore, campaign separation or dedicated equipment is the operational minimum unless closed transfer and validated cleaning provide equivalent segregation. Dispensing is conducted inside a negative-pressure isolator with HEPA filtered exhaust. The liquid extract is transferred by peristaltic pump or sanitary diaphragm pump rather than open pouring. Floor spills are addressed by immediate alkaloid deactivation and cleaning; because published strychnine-specific cleaning validation data are limited, each manufacturing site must establish swab recovery using the same HPLC assay methodology, with a detection limit below the toxicologically derived cleaning limit. Swab sites include vessel discharge valves, homogeniser shafts, and floor drains because these areas retain hydroalcoholic residues and dried alkaloid films. Cleaning validation runs should include worst-case solubility challenges; because the liquid extract is hydroalcoholic, water alone may not recover dried alkaloid residue from stainless steel, and a solvent mixture containing the same ethanol-to-water ratio as the extract may be required as the swabbing solvent. Recovery factors below 70% in swab recovery studies require correction or a different sampling solvent. The ethanol content also imposes a flammable-liquid handling requirement; storage and transfer areas should be bonded, grounded, and electrically classified according to the finish.

Regulatory acceptance of strychnine-containing veterinary finished products is not harmonised across regions. In the European Union, strychnine is not listed in Table 1 of Regulation (EU) No 37/2010; therefore, the extract cannot be used in food-producing animals under that framework. In the United States, a finished veterinary product containing Strychni Liquid Extract is an unapproved animal drug unless the marketing authorisation holder possesses an approved new animal drug application or an indexing determination. The “veterinary grade API” designation defines the manufacturing and quality-control standard of the input material; it does not itself create a completed regulatory authorisation for the finished tablet, injection, capsule, powder, granule, premix, or solution. Target-species restrictions, off-label use prohibitions, and disposal considerations for unused product remain the responsibility of the dosage-form manufacturer and the authorising regulator.

Route-specific formulation pressure points across tablet, capsule, powder, granule, premix, and solution formats

For tablets and capsules, Strychni Liquid Extract is usually adsorbed onto microcrystalline cellulose or lactose monohydrate before dry blending. In a high-shear mixer, the liquid extract is sprayed through a nozzle at controlled rate; overdosing the spray can overwet the carrier and form coarse agglomerates. The wet mass is dried in a fluid-bed dryer at an inlet air temperature not exceeding 50 °C unless forced degradation data support higher exposure; published data for this specific configuration is limited. Dried granules are milled through a 1.0 mm screen and lubricated with magnesium stearate at 0.5–1.0% w/w. Content uniformity of the tablet or capsule batch is assessed by Ph. Eur. 2.9.40 or USP <905>, with an acceptance value not exceeding 15. Tablet compression of these granulations usually requires a tablet press equipped with force feeders and dust-extraction hoods. Compression force is adjusted to a target hardness of 40–80 N for a standard round convex tablet, but the actual range is determined by dissolution, friability, and weight variation. Friability is tested per Ph. Eur. 2.9.7 and should not exceed 1.0%. For high-shear granulation, the vessel fill volume should not exceed 60% of total capacity; impeller tip speed is typically 3–6 m/s for the preliminary wet-massing phase. These values are equipment-dependent and should be confirmed by power draw or impeller torque.

Powders and granules for oral use are prepared by geometric dilution of the liquid extract onto a dry carrier or by wet granulation. When a wet granulation is selected, the solvent composition of the binding solution must be matched to the extract vehicle to avoid local alkaloid precipitation; a mix of ethanol and water in the same volumetric ratio as the extract is commonly used. The granulation end-point is determined by impeller power draw or torque on production-scale equipment, not by fixed time. For premixes, the extract is sprayed onto a feed-grade carrier such as corn cob fraction or wheat middlings inside a ribbon or paddle mixer. Distribution uniformity is validated by sampling at not fewer than 10 locations and demonstrating a relative standard deviation of not more than 5% for total alkaloids. Spray rate, carrier moisture, and nozzle droplet size are equipment-dependent; no universal mixing time applies across mill batch sizes. For oral solutions, the extract is added to a defined aqueous or hydroalcoholic vehicle. pH adjustment precedes the addition of preservatives to prevent precipitation of co-extracted botanical constituents. The solution is clarified through a 10 µm polypropylene filter or equivalent, and the filtered solution is monitored for alkaloid precipitation and colour change over the assigned shelf life. Scale-up from laboratory to production is not linear for this extract because the spray distribution and alcohol evaporation rate change with vessel geometry. Pilot-scale equipment should therefore resemble production geometry, with geometric similarity in impeller-to-vessel diameter ratio and nozzle placement.

When evaluated against isolated strychnine salts such as strychnine hydrochloride or strychnine sulfate, Strychni Liquid Extract differs in composition, assay, and handling. Isolated salts provide a single active entity and can be assayed by direct HPLC or titration with fewer co-eluting peaks. The liquid extract contains brucine and other co-extracted botanical constituents that alter total alkaloid response and may interfere when a non-selective spectrophotometric assay is transferred from a synthetic-strychnine product. Finished-product methods must therefore be validated under ICH Q2(R1) with the actual liquid extract matrix, not with a reference solution of strychnine alone. Compared with powdered nux vomica extract, the liquid extract eliminates powder dust at the point of weighing but introduces liquid spill containment, flammable solvent storage, and viscosity-related transfer losses. Compared with synthetic strychnine, the botanical source is subject to seasonal alkaloid variability; batch-to-batch adjustment of the carrier load is required to maintain the same total alkaloid dose.

Published data comparing all four material types in the same tablet or premix process is limited; the choice is therefore made on a product-specific basis using small-scale feasibility batches and the analytical method described above. The presence of brucine in the liquid extract also means that simple strychnine limit tests are insufficient for release of a finished veterinary product made from this API.

When injectable sterile filtration encounters botanical co-solutes

Injectable use of Strychni Liquid Extract is the most demanding application. The extract is not directly injectable at its delivered concentration; it must be diluted into a suitable vehicle under aseptic conditions. The presence of co-extracted botanical solutes means that sterile filtration cannot be validated with a surrogate alkaloid solution alone. Filter compatibility must be tested with the actual diluted extract because the hydroalcoholic vehicle may extract membrane components or cause reduced flow. pH and temperature excursions during sterile filtration can precipitate brucine or other co-extractives in the filter housing. A filtration trial should be conducted at the target product temperature, typically 20–25 °C, and the differential pressure across the membrane should be monitored; a rapid pressure rise indicates membrane fouling or precipitation.

The filtered solution must meet sterility per Ph. Eur. 2.6.1 and bacterial endotoxin limits per Ph. Eur. 2.6.14. If terminal steam sterilisation at 121 °C for 15 min is proposed, published stability data for this specific extract in the finished injection vehicle are limited; an aseptic filtration process is therefore preferred unless terminal sterilisation is supported by a validated strychnine and brucine assay before and after the cycle. A 0.22 µm PVDF or PES membrane may be assessed, but the selected membrane must show no extractable interference in the strychnine HPLC chromatogram. The product label for an injectable finished form must state the total alkaloid content, the strychnine content, the brucine content, and the parenteral vehicle; omission of brucine data creates analytical and toxicological uncertainty. Because strychnine distributes rapidly after injection and has a narrow margin, the manufacturing process must ensure dose uniformity to the same acceptance value as for tablets, and the batch record must document the fill volume tolerance and in-process assay at the beginning, middle, and end of the filling campaign.